| Literature DB >> 26607152 |
Luciana A Naves1, Adrian F Daly2, Luiz Augusto Dias3, Bo Yuan4, Juliano Coelho Oliveira Zakir5, Gustavo Barcellos Barra6, Leonor Palmeira2, Chiara Villa2,7, Giampaolo Trivellin8, Armindo Jreige Júnior5, Florêncio Figueiredo Cavalcante Neto9, Pengfei Liu4, Natalia S Pellegata10, Constantine A Stratakis8, James R Lupski4,11,12,13, Albert Beckers14.
Abstract
X-linked acro-gigantism (X-LAG) syndrome is a newly described disease caused by microduplications on chromosome Xq26.3 leading to copy number gain of GPR101. We describe the clinical progress of a sporadic male X-LAG syndrome patient with an Xq26.3 microduplication, highlighting the aggressive natural history of pituitary tumor growth in the absence of treatment. The patient first presented elsewhere aged 5 years 8 months with a history of excessive growth for >2 years. His height was 163 cm, his weight was 36 kg, and he had markedly elevated GH and IGF-1. MRI showed a non-invasive sellar mass measuring 32.5 × 23.9 × 29.1 mm. Treatment was declined and the family was lost to follow-up. At the age of 10 years and 7 months, he presented again with headaches, seizures, and visual disturbance. His height had increased to 197 cm. MRI showed an invasive mass measuring 56.2 × 58.1 × 45.0 mm, with compression of optic chiasma, bilateral cavernous sinus invasion, and hydrocephalus. His thyrotrope, corticotrope, and gonadotrope axes were deficient. Surgery, somatostatin analogs, and cabergoline did not control vertical growth and pegvisomant was added, although vertical growth continues (currently 207 cm at 11 years 7 months of age). X-LAG syndrome is a new genomic disorder in which early-onset pituitary tumorigenesis can lead to marked overgrowth and gigantism. This case illustrates the aggressive nature of tumor evolution and the challenging clinical management in X-LAG syndrome.Entities:
Keywords: FIPA; GPR101; Giant; Pituitary adenoma; X-linked acro-gigantism syndrome
Mesh:
Year: 2015 PMID: 26607152 PMCID: PMC5497487 DOI: 10.1007/s12020-015-0804-6
Source DB: PubMed Journal: Endocrine ISSN: 1355-008X Impact factor: 3.633